0000000000538920

AUTHOR

Yunlong Xia

showing 2 related works from this author

Frailty and Mortality Outcomes After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

2017

Abstract Background Frailty has been identified as a risk factor for mortality. However, whether frailty increases mortality risk in patients undergoing percutaneous coronary intervention (PCI) has been controversial. Therefore, we conducted a systematic review and meta-analysis of the frailty measures and mortality outcomes in this setting. Methods PubMed and EMBASE were searched until July 23, 2017 for studies evaluating the association between frailty measures and mortality in individuals who have undergone PCI. Results A total of 141 entries were retrieved from our search strategy. A total of 8 studies involving 2332 patients were included in the final meta-analysis (mean age: 69 years;…

Malemedicine.medical_specialtymedicine.medical_treatmentSubgroup analysisCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionPredictive Value of TestsInternal medicineCause of DeathmedicineHumans030212 general & internal medicineRisk factorGeneral NursingAgedProportional Hazards ModelsFrailtybusiness.industryHealth PolicyMortality rateHazard ratioPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival AnalysisConfidence intervalTreatment OutcomeMeta-analysisConventional PCIMultivariate AnalysisFemaleMedical emergencyGeriatrics and GerontologybusinessJournal of the American Medical Directors Association
researchProduct

Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo

2018

Source at https://doi.org/10.3389/fmicb.2018.00530 . Background: Statin has been widely used to treat hyperlipidemia because of its high potency in decreasing cholesterol levels. The present study aimed to examine the lipid-lowering effect of rosuvastatin and the composition, diversity and species abundance of gut microbiome in association with rosuvastatin efficacy. TRIAL REGISTRATION: ChiCTR-ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2, 2017. Results:Totally 64 patients with hyperlipidemia were treated with 10 mg/day of rosuvastatin for 4-8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), lo…

0301 basic medicineMicrobiology (medical)Statinmedicine.drug_classlcsh:QR1-502PhysiologyBlood lipidsgut microbiomeBiologyGut floraMicrobiologylcsh:Microbiology03 medical and health scienceschemistry.chemical_compoundHigh-density lipoproteinHyperlipidemiamedicinehyperlipidemiaRosuvastatinVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Cardiology: 771VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771CholesterolVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Pharmacology: 728nutritional and metabolic diseasesFusobacteriaVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Medical microbiology: 715medicine.diseasebiology.organism_classification16S rRNA sequencing030104 developmental biologychemistryVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728lipids (amino acids peptides and proteins)hypolipidemic effectrosuvastatinmedicine.drugFrontiers in Microbiology
researchProduct